Abstract Number: 502 • 2015 ACR/ARHP Annual Meeting
Decreased Vaccine Responses in Rheumatoid Arthritis Patients Receiving Anti-TNF Treatment and Relationship to B Cell Subsets
Background/Purpose: TNF is a key pro-inflammatory cytokine in normal immune responses and pathologically in the rheumatoid arthritis (RA) synovium, thus representing a key treatment target…Abstract Number: 503 • 2015 ACR/ARHP Annual Meeting
Predictors for Attaining Remission at Two Consecutive Visits in Newly Diagnosed Early RA Patients
Background/Purpose: Early and intensive treatment with DMARDs are essential for remission induction in newly diagnosed RA patients. However, demographic, psychosocial and disease related factors may…Abstract Number: 504 • 2015 ACR/ARHP Annual Meeting
Influence of CDAI Measurement on the Decision of Community Rheumatologists to Initiate or Change Biologic Treatment
Background/Purpose: Periodic measurement of disease activity using validated tools such as the Clinical Disease Activity Index (CDAI) is considered an important aspect of care for…Abstract Number: 505 • 2015 ACR/ARHP Annual Meeting
Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Certolizumab, Etanercept, Infliximab, Rituximab and Tocilizumab in a Real World Routine Care Registry
Background/Purpose: With the availability of multiple biologic agents, each with different modes of action, use of real world registries provide the manner in which to…Abstract Number: 506 • 2015 ACR/ARHP Annual Meeting
Evaluation of Persistence and Outcomes in Patients Treated with TNF and Non-TNF Biologics Following Treatment Clinical Pathway in Rheumatoid Arthritis
Background/Purpose: Use of biologic agents for the treatment of rheumatoid arthritis continues to grow rapidly, with the cost of these agents putting a significant strain…Abstract Number: 507 • 2015 ACR/ARHP Annual Meeting
Meta-Analysis of the Time Course of the Response to Adalimumab Plus Methotrexate or Methotrexate Monotherapy in Clinical Trials of Patients with Rheumatoid Arthritis
Background/Purpose: Adalimumab (ADA) plus methotrexate (MTX) and MTX treatments for rheumatoid arthritis (RA) have been assessed in phase 2–4 clinical trials. This meta-analysis used 5…Abstract Number: 508 • 2015 ACR/ARHP Annual Meeting
Impact of Race on Patient Global Scores and the Misclassification of Disease Activity
Background/Purpose: Disease activity measurement is a cornerstone of the Treat to Target strategy. However, all currently used measures include a Patient Global Score (PtGLB )…Abstract Number: 509 • 2015 ACR/ARHP Annual Meeting
In Early Undifferentiated Polyarthritis, 14-3-3η Seroreversion or Sustained Negativity Is Associated with Better Radiographic Outcomes, Even in DAS-28 Remitters
Background/Purpose: Advancements in RA treatment approaches with DMARDs and biological agents have enabled disease remission goals that were previously considered unattainable. The concept of "tight…Abstract Number: 510 • 2015 ACR/ARHP Annual Meeting
Histologic Scoring of Arthroplasty Synovial Samples May Predict RA Flare
Background/Purpose: Patients with established RA undergoing total joint arthroplasty (TJA) frequently experience a disease flare within 6 weeks of surgery. This study aims to determine…Abstract Number: 511 • 2015 ACR/ARHP Annual Meeting
Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient
Background/Purpose: In clinical practice in rheumatoid arthritis (RA), it has been noted that each anti-rheumatic therapy delivers a different outcome for individual RA patients and…Abstract Number: 512 • 2015 ACR/ARHP Annual Meeting
Physical Function and Inflammatory Activity in Rheumatoid Arthritis Patients. Is Disease Duration Important?
Background/Purpose: HAQ (Health Assessment Questionnaire) assesses functional disability in rheumatoid arthritis (RA) patients. Correlation between HAQ and disease activity might change according to the length…Abstract Number: 513 • 2015 ACR/ARHP Annual Meeting
Cumulative Association of Genetic Variants with Rheumatoid Joint Damage Progression in Mexican Americans and European Americans
Background/Purpose: Genealogical and genetic association studies have suggested that joint damage in rheumatoid arthritis (RA) may be heritable. We and others have found a number…Abstract Number: 514 • 2015 ACR/ARHP Annual Meeting
MRI Bone Oedema at Enrollment Predicts the Development of Rapid Radiographic Progression at 1 Year Toward Patients with Early-Stage Rheumatoid Arthritis: Results from Nagasaki University Early Arthritis Cohort
Background/Purpose: To clarify whether MRI bone oedema predicts the development of rapid radiographic progression (RRP) in Nagasaki University Early Arthritis Cohort patients with early-stage rheumatoid…Abstract Number: 515 • 2015 ACR/ARHP Annual Meeting
Are Changes in Autoantibody Levels Reflecting Change in Prognosis of Rheumatoid Arthritis?
Background/Purpose: The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) is associated with progression of joint damage in patients with rheumatoid arthritis…Abstract Number: 516 • 2015 ACR/ARHP Annual Meeting
Immunological and Ultrasound Characteristics of Patients with Rheumatoid Arthritis in Clinical Remission – Can We Use These to Predict Outcomes?
Background/Purpose: Remission is the key treatment goal in rheumatoid arthritis (RA). Although clinical remission is increasingly achieved, many patients progress both structurally and functionally. We…
ACR Meeting Abstracts